Efficacy of stereotactic radiotherapy combined with chemotherapy for local recurrent non-small-cell lung cancer after radiotherapy
10.3781/j.issn.1000-7431.2009.12.007
- VernacularTitle:立体定向放射治疗联合化疗治疗放疗后局部复发非小细胞肺癌的疗效
- Author:
Zhao DONG
;
Qi LI
;
Qingliang QIN
;
Yong GAO
- Publication Type:Journal Article
- Keywords:
Lung neoplasms;
Carcinoma;
non-small-cell lung;
Stereotactic radiotherapy;
Drug therapy;
Recurrence;
Survival rate
- From:
Tumor
2009;(12):1133-1136
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the efficacy of stereotactic radiotherapy (SRT) combined with gemcitabine plus cisplatin (GP)-based chemotherapy on local recurrent non-small-cell lung cancer (NSCLC) after radiotherapy. Methods:Thirty-eight patients with local recurrent NSCLC were treated with SRT(3.00-4.85 Gy per fraction, five times every week, totally 8-12 fractions, total course of 2-3 weeks). Before SRT the patients were given two cycles of GP-based chemotherapy (gemcitabine 1 000 mg/m~2 d 1 and d 8;cisplatin 30 mg/m~2 d 1-3) and at the end of SRT they were given 4 cycles of GP-based chemotherapy. Results:Of the 38 patients,7 patients had complete response, and 23 patients achieved partial response. The overall immediate response rate was 78.95% (30/38). The 6-month and 12-month total survival rates were 71.05% and 10.53%,respectively. The median survival time was 7.8 months. Conclusion:SRT combined with GP-based chemotherapy had better short-term efficacy and the patients were tolerable. No severe short-term radiation-induced injury was observed. The long-term radiation-induced injury and long-term efficacy need further investigation.
